Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Implementing HIV pre-exposure prophylaxis (PrEP): let's not get caught with our pants down.

Peter Saxton1, Massimo Giola2, Edward Coughlan3

  • 1Director, Gay Men's Sexual Health Research Group, Department of Social and Community Health, University of Auckland, Auckland.

The New Zealand Medical Journal
|August 31, 2018
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pediatric blastic plasmacytoid dendritic cell neoplasms are molecularly defined by recurrent <i>MYB</i> rearrangements: clinical and molecular insights.

Haematologica·2026
Same author

Diagnoses of blood-borne viruses and other sexually transmitted infections in a sample of 356 sex workers attending a sexual health outreach clinic in Auckland over a two-year period.

The New Zealand medical journal·2026
Same author

Transcriptomic and epigenetic profiling of neuroblastoma states in response to RBM39 degrader.

Scientific data·2025
Same author

Shared burden of ultra-rare genetic variants across a spectrum of motor neuron diseases.

Translational neurodegeneration·2025
Same author

A systematic review of models used to estimate undiagnosed HIV prevalence in high income low prevalence countries and territories.

AIDS (London, England)·2025
Same author

Position statement on doxycycline post-exposure prophylaxis for the prevention of bacterial sexually transmissible infections in Aotearoa New Zealand: the New Zealand Sexual Health Society.

Sexual health·2025

Daily HIV pre-exposure prophylaxis (PrEP) pills can prevent HIV. New Zealand

Area of Science:

  • Public Health
  • Infectious Disease Prevention
  • HIV/AIDS Research

Background:

  • HIV pre-exposure prophylaxis (PrEP) is a daily medication proven to prevent HIV acquisition.
  • New Zealand initiated publicly funded PrEP in March 2018 for high-risk individuals.
  • Widespread unfamiliarity among health practitioners hinders PrEP's potential impact in New Zealand.

Purpose of the Study:

  • To review the rationale and benefits of implementing PrEP in New Zealand.
  • To identify key barriers impeding the rapid and effective scale-up of PrEP services.
  • To highlight areas for research and innovation to optimize PrEP delivery.

Main Methods:

  • Literature review on PrEP efficacy and implementation strategies.
  • Analysis of potential barriers to PrEP uptake and service delivery in the New Zealand context.

Related Experiment Videos

  • Identification of policy, training, and systemic factors influencing PrEP access.

    • Main Results:

    • Significant barriers to PrEP implementation include low awareness, acceptability issues, and prescribing bottlenecks.
    • Challenges exist in service capacity for follow-up care, primary care training, and monitoring systems.
    • Equity, eligibility criteria, and policy considerations require careful management for successful PrEP scale-up.

    Conclusions:

    • Addressing identified barriers is crucial for realizing the full potential of PrEP in New Zealand.
    • Optimizing PrEP implementation can significantly contribute to controlling HIV transmission.
    • Further research and innovation are needed to overcome obstacles and advance towards ending HIV in Aotearoa/New Zealand.